References
- Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6: 16. DOI:10.1038/s41421-020-0156-0. eCollection 202.
- Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020: 105949. DOI:10.1016/j.ijantimicag.2020.105949.
- Yao X, Ye F, Zhang M, et al. In Vitro Antiviral activity and projection of optimized dosing design of Hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020. pii: ciaa237. DOI:10.1093/cid/ciaa237.
- Savarino A, Di Trani L, Donatelli I, et al. New insights into the antiviral effects of chloroquine. Lancet Infect Dis. 2006; 6:67–69. DOI:10.1016/S1473-3099(06)70361-9.
- McChesney EW. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am. J. Med. 1983; 75(1A):11–18. DOI:10.1016/0002-9343(83)91265-2.
- Zhou D, Dai SM, Tong Q, et al. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J. Antimicrob. Chemother. 2020: dkaa114. DOI:10.1093/jac/dkaa114.
- Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30:269–271. DOI:10.1038/s41422-020-0282-0.
- Zhou P, Yang X, Wang X, et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. Nature. 2020; 579:270–273. DOI:10.1038/s41586-020-2012-7.
- Guastalegname M, Vallone A. Could ahloroquine/hydroxychloroquine be harmful in coronavirus disease 2019 (COVID-19) treatment? Clin Infect Dis. 2020. pii: ciaa321. DOI:10.1093/cid/ciaa321.
- Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020; 14(1):69–71. DOI:10.5582/bst.2020.01020.
- Laaksonen AL, Koskiahde V, Juva K. Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. A clinical study with determination of serum concentrations of chloroquine and hydroxychloroquine. Scand. J. Rheumatol. 1974; 3(2):103–108.
- Furst DE, Lindsley H, Baethge B, et al. Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension. Arthritis Rheum. 1999; 42(2):357–365.
- Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation. 2012; 126(1):76–82. DOI:10.1161/CIRCULATIONAHA.111.089268.
- Lisney AR, Szelinski F, Reiter K, et al. High maternal expression of SIGLEC1 on monocytes as a surrogate marker of a type I interferon signature is a risk factor for the development of autoimmune congenital heart block. Ann. Rheum. Dis. 2017; 76(8):1476–1480. DOI:10.1136/annrheumdis-2016-210927.
- Misra DP, Agarwal V, Gasparyan AY, et al. Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol. 2020. DOI:10.1007/s10067-020-05073-9.